Cargando…
Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970364/ https://www.ncbi.nlm.nih.gov/pubmed/35358286 http://dx.doi.org/10.1371/journal.pone.0266625 |
| _version_ | 1784679443516620800 |
|---|---|
| author | de Jong, Lisa A. Groeneveld, Jessie Stevanovic, Jelena Rila, Harrie Tieleman, Robert G. Huisman, Menno V. Postma, Maarten J. van Hulst, Marinus |
| author_facet | de Jong, Lisa A. Groeneveld, Jessie Stevanovic, Jelena Rila, Harrie Tieleman, Robert G. Huisman, Menno V. Postma, Maarten J. van Hulst, Marinus |
| author_sort | de Jong, Lisa A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8970364 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89703642022-04-01 Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings de Jong, Lisa A. Groeneveld, Jessie Stevanovic, Jelena Rila, Harrie Tieleman, Robert G. Huisman, Menno V. Postma, Maarten J. van Hulst, Marinus PLoS One Correction Public Library of Science 2022-03-31 /pmc/articles/PMC8970364/ /pubmed/35358286 http://dx.doi.org/10.1371/journal.pone.0266625 Text en © 2022 de Jong et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction de Jong, Lisa A. Groeneveld, Jessie Stevanovic, Jelena Rila, Harrie Tieleman, Robert G. Huisman, Menno V. Postma, Maarten J. van Hulst, Marinus Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| title | Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| title_full | Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| title_fullStr | Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| title_full_unstemmed | Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| title_short | Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| title_sort | correction: cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970364/ https://www.ncbi.nlm.nih.gov/pubmed/35358286 http://dx.doi.org/10.1371/journal.pone.0266625 |
| work_keys_str_mv | AT dejonglisaa correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT groeneveldjessie correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT stevanovicjelena correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT rilaharrie correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT tielemanrobertg correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT huismanmennov correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT postmamaartenj correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings AT vanhulstmarinus correctioncosteffectivenessofapixabancomparedtootheranticoagulantsinpatientswithatrialfibrillationintherealworldandtrialsettings |